Cargando…
Cost of leukopenia and neutropenia in metastatic breast cancer within last 12, 36, and 60 months using a curated disease model
Background: Evaluating changes to historical treatment costs is critical for healthcare professionals to make informed business decisions. However, real-world clinical and cost outcome data is challenging to use regularly without significant data science knowledge or resources. Aims: This study soug...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764399/ http://dx.doi.org/10.1080/21556660.2019.1658301 |